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Abstract
Background: Galectin-3, a biomarker associated with fibrosis and inflammation, has been 
implicated in development and progression of heart failure (HF) and predicts increased morta­
lity and morbidity in this condition. HF frequently develops after myocardial infarction (MI), 
contributing to worse outcome. The aim of this study is to assess the association between ga­
lectin-3 levels and various clinical parameters in acute phase of first MI treated with primary 
percutaneous coronary intervention (pPCI) in patients without prior HF.
Methods: We included 145 consecutive patients with first acute MI treated with pPCI with 
stent implantation. Exclusion criteria were: prior HF, severe valvular diseases, coexisting can­
cers, connective tissue diseases and cirrhosis. Serum galectin­3 concentration was measured 
within 3–5 days after onset of acute MI. 
Results: Thirty­six patients with the highest galectin­3 levels (4th quartile, > 16 ng/mL) were 
compared to 109 subjects with a biomarker concentration ≤ 16 ng/mL. Elevated galectin­3 
levels were more often observed in females, the elderly, subjects with coexisting diabetes, renal 
dysfunction and permanent atrial fibrillation (AF). Galectin-3 correlated with N-terminal 
pro­B­type natriuretic peptide (r = 0.27, p < 0.001) and high­sensitivity C­reactive protein  
(r = 0.20, p < 0.05). Multivariate analysis revealed that only new-onset AF and diuretics treat- 
ment during hospitalization were independently associated with galectin­3 levels > 16 ng/mL. 
Conclusions: Elevated galectin-3 levels were associated with a higher rate of new-onset AF 
and diuretics treatment during hospitalization in patients with first MI treated with pPCI 
without prior HF. (Cardiol J 2013; 20, 6: 577–582)
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Introduction
Galectin-3, a soluble beta-galactoside-binding 
lectin, is secreted by activated macrophages and 
modulates several physiological and pathological 
processes, including inflammation and fibrosis. 
This protein directly induces fibroblasts to prolife-
rate and deposit type I collagen in the extracellular 
matrix [1, 2]. The involvement of galectin-3 in the 
development and progression of fibrosis has been 
demonstrated in various organs, for example in the 
liver [3], kidney [4] and heart [2].
Despite improvements in the diagnosis and 
therapy of cardiovascular diseases, heart failure 
(HF) is still associated with a high morbidity and 
mortality [5, 6]. Several biomarkers are used for 
early diagnosis and risk stratification in this group 
of patients. Galectin-3 levels are elevated in vario-
us cohorts of HF patients and independently asso-
ciated with higher risk of death, HF progression 
and rehospitalization [7–12]. 
Myocardial infarction (MI) is one of the major 
causes of HF. Primary percutaneous coronary in-
tervention (pPCI), as a reperfusion method in acute 
MI, plays an important role in the prevention of 
death and HF development [13, 14]. We hypothe-
sized that galectin-3 measurement in acute phase 
of MI could provide additional useful information 
in this group of patients. The aim of this study is 
to assess the association between galectin-3 levels 
and various clinical parameters in subjects with 
first MI treated with pPCI without prior HF.
Methods 
We included 145 consecutive patients with 
first acute MI (type I) [15] treated with pPCI with 
stent implantation (96 patients with ST-elevation 
MI [STEMI], 49 patients with non-STEMI). Exclu-
sion criteria were: prior HF, severe valvular dise-
ases (qualified for surgical treatment), coexisting 
cancers, connective tissue diseases and cirrhosis. 
Peripheral blood samples were obtained within 
3–5 days after acute MI and the serum was frozen 
at –70°C until tested. The serum levels of galectin-3 
(VIDAS, bioMérieux), N-terminal pro-B-type na-
triuretic peptide (NT-proBNP) (Cobas e411, Roche 
Diagnostics) and high-sensitivity C-reactive protein 
(hsCRP) (AU680, Beckman Coulter) were measu-
red. Glomerular filtration rate (GFR) was calculated 
using the Cockroft-Gault’ formula. Transthoracic 
echocardiography was performed on the 3rd–5th day 
of MI. Left ventricular ejection fraction (EF) was 
assessed by the modified Simpson’s formula.
The study protocol was approved by Bioethics 
Committee of the Medical University of Lodz. All 
subjects gave their informed consent for partici-
pation in the study. 
Statistical analysis
In the statistical analysis results were pre-
sented as mean ± standard deviation (SD) for 
continuous variables and as percent for categori-
cal variables. Differences in categorical variables 
between groups were evaluated with the c2 test. 
Differences between mean values for continuous 
variables were evaluated with the Student t test or 
the Mann-Whitney U test. We assessed the correla-
tion between galectin-3, NT-proBNP, hsCRP and 
EF using the Spearman rank correlation coefficient. 
Logistic regression was used to estimate the as-
sociation between discrete dependent and continu-
ous variables or discrete independent variables. 
Potential predictors of elevated levels of galectin-3 
were subjected to a univariate risk analysis model 
of logistic regression. To determine the strongest 
and most independent predictors, independent 
variables significantly changing the matching 
of univariable models were included in multi-
variate model. The level of significance p < 0.05 
was accepted for all the tests used. Statistical 
analysis was facilitated by the use of STATISTICA 
10 PL (StatSoft Polska, Krakow, Poland).
Results
The study included 145 consecutive patients 
with first acute MI treated with pPCI with stent 
implantation (104 men and 41 women aged between 
32 and 88 years, mean age 62.1 ± 10.3 years). 
We divided galectin-3 levels (ng/mL) in quartiles 
(1st quartile: 6.1–10.9; 2nd quartile: 11.0–13.3; 
3rd quartile: 13.4–16.0; 4th quartile: 16.4–41.0). The 
mean value of serum galectin-3 concentration was 
14.7 ± 6.2 ng/mL. Thirty-six patients with the 
highest galectin-3 serum concentration (4th quartile, 
> 16 ng/mL) were included in the study group, 
whereas the other 109 (75%) subjects with a bio-
marker concentration ≤ 16 ng/mL were assigned 
to the control group. The specific characteristic of 
the groups are shown in Table 1.
Patients with elevated levels of galectin-3 
were more often females, were older and more 
often presented with diabetes and permanent 
atrial fibrillation (AF). In addition, differences in 
mean values of glucose, creatinine, GFR, uric 
acid, NT-proBNP and hsCRP were all statistically 
significant between the study and control groups. 
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Differences in other parameters were not statisti-
cally significant. 
In our study, only 10 (6.9%) patients had 
decreased EF (< 40%), 67 (46.2%) patients had 
preserved EF (41–54%) and 68 (46.9%) patients 
normal EF (≥ 55%). Galectin-3 levels were not 
significantly associated with EF (r = –0.003, 
p > 0.05). In the analysis of serum biomarkers we 
observed a positive correlation between galectin-3 
and NT-proBNP (r = 0.27, p < 0.001), galectin-3 
and hsCRP (r = 0.20, p < 0.05), NT-proBNP and 
hsCRP levels (r = 0.45, p < 0.001). 
We compared in-hospital clinical events in 
patients with elevated galectin-3 levels to the 
control group (Table 2). There were no differences 
in frequency of ventricular arrhythmias (ventricu- 
lar fibrillation and ventricular tachycardia) and pres-
sor amines therapy. Patients with galectin-3 levels 
> 16 ng/mL more often had new-onset AF in acu-
te phase of MI (p < 0.05), new diagnosis of HF 
Table 1. Characteristics of study and control group.
Study group (n = 36)
Galectin-3 > 16 ng/mL
Control group (n = 109)
Galectin-3 ≤ 16 ng/mL
P
Women 16 (44.4%) 25 (22.9%) < 0.05
Age [years] 68.2 ± 9.6 59.7 ± 9.8 < 0.001
Hypertension 29 (80.6%) 81 (74.3%) NS
Diabetes 12 (33.3%) 16 (14.7%) < 0.05
Permanent AF 5 (13.9%) 3 (2.7%) < 0.05
Body mass index [kg/m2] 28.8 ± 4.2 27.3 ± 4.8 NS
ST-elevation myocardial infarction 24 (66.7%) 72 (66.0%) NS
Troponin T max [ng/mL] 2.57 ± 2.6 3.1 ± 3.4 NS
Glycemia on admission [mmol/L] 9.48 ± 4.3 8.09 ± 3.9 < 0.01
Total cholesterol [mmol/L] 5.34 ± 1.29 5.31 ±1.19 NS
LDL-cholesterol [mmol/L] 3.3 ± 1.1 3.2 ± 1.0 NS
HDL-cholesterol [mmol/L] 1.37 ± 0.49 1.31 ± 0.37 NS
Triglycerides [mmol/L] 2.12 ± 1.6 1.67 ± 0.9 NS
Creatinine [µmol/L] 88.5 ± 28.7 75.9 ±19.7 < 0.05
GFR [ml/min/L] 87.9 ± 38.8 109.6 ±37.7 < 0.01
Fibrinogen [g/L] 3.91 ± 1.7 4.11 ± 3.43 NS
Uric acid [µmol/L] 371.0 ± 89.5 310.0 ± 87.5 < 0.01
NT-proBNP [pg/mL] 3309 ± 2957 1030 ± 793 < 0.01
hsCRP [mg/L] 58.7 ± 74 25.7 ± 29 < 0.05
Ejection fraction [%]  54.3 ± 9.7 55.0 ± 9.5 NS
AF — atrial fibrillation; GFR — glomerular filtration rate; NT-proBNP — N-terminal pro-B-type natriuretic peptide; hsCRP — high-sensitivity 
C-reactive protein
Table 2. Comparison of clinical events during hospitalization in study and control group.
Study group (n = 36)
Galectin-3 > 16 ng/mL
Control group (n = 109)
Galectin-3 ≤ 16 ng/mL
P
Ventricular fibrillation 2 (5.6%) 3 (2.7%) NS
Ventricular tachycardia 1 (2.8.%) 3 (2.7%) NS
New-onset atrial fibrillation 7 (19.4%) 3 (2.7%) < 0.05
Diagnosis of heart failure 11 (30.6%) 17 (15.6%) < 0.05
Pressor amines therapy 0 (0%) 5 (4.6%) NS
Diuretics treatment 17 (47.2%) 16 (14.7%) < 0.001
Aldosterone antagonists treatment 9 (25%) 16 (14.7%) NS
Infections 16 (44.4%) 29 (26.6%) < 0.05
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(p < 0.05), in-hospital infections (pneumonia, upper 
respiratory tract infection, urinary tract infection; 
p < 0.05), and more often needed diuretic treatment 
because of symptoms (p < 0.001). There was no dif-
ference in diuretic therapy before admission between 
study and control group (11.1% vs. 9.2%, p > 0.05). 
In univariate analysis (Table 3) there was 
a significant association between elevated galec-
tin-3 levels > 16 ng/mL and female gender (OR = 
= 2.69, p < 0.05), age > 65 years (OR = 3.74, 
p < 0.01), diabetes (OR = 2.9, p < 0.05), GFR 
(OR = 0.98, p < 0.01), new-onset AF (OR = 5.7, 
p < 0.05), diuretic treatment (OR = 5.2, p < 0.001) 
and in-hospital infections (OR = 2.86, p < 0.01). 
Multivariate analysis revealed that only in-hospital 
new-onset AF (OR = 6.23, 95% CI 1.08–36.0, 
p < 0.05) and diuretic treatment (OR = 2.67, 
95% CI 0.96–7.42, p = 0.05) were independently 
associated with elevated galectin-3 levels (Fig. 1).
Discussion
Galectin-3 has recently been widely studied 
as a prognostic biomarker in a variety of HF co-
horts. The majority of these included patients with 
symptomatic HF and decreased EF. For example, 
the Coordinating Study Evaluating Outcomes of 
Advising and Counseling in Heart Failure (COACH) 
enrolled 1023 subjects in New York Heart 
Association (NYHA) functional class II–IV (50% 
were in NYHA IV class) and EF ≤ 35% (mean 
33 ± 15%) [6]. In a sub-study of the COACH co-
hort (n = 592), the median value of galectin-3 was 
20 ng/mL (range 5.0–66.6 ng/mL) and a doubling of 
its level was associated with a significant increased 
risk for all-cause mortality and HF hospitalization 
during 18-month follow-up (HR 1.97, p < 0.001) 
[12]. Myocardial injury generates inflammatory 
and fibrosis signals that activate macrophages and 
stimulate galectin-3 secretion, although in our 
observation, patients in acute phase of first MI 
without prior HF had notably lower levels of this 
serum biomarker in comparison to subjects with 
chronic cardiac injury in the literature [8–12]. The-
re are only a small numbers of studies concerning 
galectin-3 measurement in patients with MI. Data 
from the Pravastatin or Atorvastatin Evaluation and 
Infection Therapy-Thrombolysis In Myocardial In-
farction 22 trial (PROVEIT-TIMI 22) demonstrated 
that galectin-3 values above 16.7 µg/L (median), 
measured within 7 days after acute coronary syn-
drome, was significantly associated with higher 
risk of HF development during 2-year follow-
-up, but elevated levels of this biomarker were 
observed mostly in patients with hypertension, 
diabetes, prior HF and prior MI [16]. Falcone et al. 
[17] analyzed a group of patients with angiographi-
cally documented coronary artery disease: unstable 
patients (n = 55) had higher galectin-3 levels in 
Table 3. Univariate analysis: the parameters associated with elevated galectin-3 levels (> 16 ng/mL) in 
patients with first acute myocardial infarction treated with primary percutaneous coronary intervention.
Odds ratio 95% confidence interval P
Women 2.69 1.2–5.9 < 0.05
Age > 65 years 3.74 1.67–8.37 < 0.01
Diabetes 2.9 1.21-7.0 < 0.05
Glomerular filtration rate 0.98 0.97–0.99 < 0.01
New-onset atrial fibrillation 5.7 1.27–25.5 < 0.05
Diuretics treatment 5.2 2.22–12.2 < 0.001
In-hospital infections 2.86 1.29–6.33 < 0.01
Figure 1. Multivariate analysis: the parameters independen-
tly associated with elevated galectin-3 levels (> 16 ng/mL) 
in patients with first acute myocardial infarction trea-
ted with primary percutaneous coronary intervention 
(with 95% confidence interval); AF — atrial fibrillation; 
OR — odds ratio.
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comparison to the stable subjects (27.75 ng/mL vs. 
6.48 ng/mL, p < 0.001). Compared with these stu-
dies, we observed lower galectin-3 concentrations 
in our group of patients (median 13.0 ng/mL), which 
could be explained by our restrictive inclusion and 
exclusion criteria. Additionally, all subjects were 
successfully treated with pPCI with stent implan-
tation — the best method for the prevention of ad-
verse cardiovascular events, severe cardiac injury 
and remodeling processes. The parameter most 
frequently used for assessment of left ventricular 
dysfunction is EF, determined by echocardiograp-
hy. In the literature, no significant or only weak 
correlation between galectin-3 levels and EF was 
demonstrated, which confirms our observation 
(r = –0.003, p > 0.05) [9, 16]. 
Galectin-3, a protein linking processes of 
inflammation and fibrosis, is often compared with 
other prognostic biomarkers in patients with HF 
[7–10, 12, 16]. Galectin-3 levels are relatively stable 
over time (independent of HF decompensation or 
HF treatment), whereas NT-proBNP is released in 
response to current myocardial stretch. In the NT-
-proBNP investigation of dyspnea in the emergency 
department (PRIDE) study, baseline galectin-3 level 
was a superior predictor of short and long-term 
mortality in patients with acute HF and only mode-
rately correlated with NT-proBNP concentration 
(r = 0.39, p < 0.001) [7]. In another group of patients 
with severe chronic HF, galectin-3 measurement 
provided prognostic information for predicting 
survival, independent of natriuretic peptides [9]. 
No significant correlation between galectin-3 and 
BNP levels was observed in subjects with HF de-
velopment after acute coronary syndrome [16]. In 
our study there was a weak relationship between 
3 measured biomarkers: galectin-3, NT-proBNP 
and hsCRP, which support previous observations 
that these proteins reflect different pathways in the 
pathobiology of cardiac injury [1, 2, 7, 8, 9, 12, 16].
Galectin-3 has been validated as an indepen-
dent long-term prognostic marker in patients with 
HF, but not in subjects in acute phase of MI without 
prior heart insufficiency. As previously demon-
strated, we found that galectin-3 levels depend on 
age, gender, renal dysfunction and are elevated in 
patients with diabetes and chronic AF [6–9, 11, 
12, 16, 18, 19]. After analyzing the appearance of 
clinical events during hospitalization, we observed 
a higher rate of new diagnosis of HF, new-onset 
AF, in-hospital infections and diuretics treatment, 
but not ventricular arrhythmias or pressor amines 
therapy in patients with galectin-3 concentration 
> 16 ng/mL. The novel observation of our study is 
a higher rate of new-onset AF in acute phase of 
MI in patients with elevated galectin-3 levels. 
Swartz et al. [20] have also observed the corre-
lation between serum markers for collagen I and 
III synthesis and appearance of post-operative AF 
[20], which confirms that fibrosis processes play an 
important role in pathobiology of this arrhythmia. 
To conclude, in the present analysis of a re-
latively homogeneous group of patients with first 
MI effectively treated with pPCI, with exclusion 
of other diseases able to modulate galectin-3 va-
lues, the new-onset AF during hospitalization was 
independently associated with elevated levels of 
galectin-3 (> 16 ng/mL). Although we did not ob-
serve an independent association of a higher rate of 
early development of HF with elevated galectin-3, 
such patients more often needed diuretic treatment 
due to clinical symptoms.
Limitations of the study 
A limitation of our study is its small sample 
size. It is probably associated with the fact that 
only part of the subjects meeting our inclusion and 
exclusion criteria (first MI, no history of prior HF, 
absence of severe valvular impairment or other 
coexisting diseases) had elevated galectin-3 levels. 
Moreover, treatment with pPCI plays an important 
role in the prevention of cardiovascular events and 
development of HF after acute MI, which additio-
nally influences our results.
Conclusions
Our study confirms the association between 
galectin-3 levels and patients’ age, gender, diabe-
tes, permanent AF and renal dysfunction. Increased 
levels of this biomarker are independently asso-
ciated with new-onset AF and diuretic treatment 
during hospitalization in patients with first acute 
MI treated with pPCI without prior HF. The only 
weak to moderate relationship between galectin-3, 
hsCRP and NT-proBNP indicates that galectin-3 
reflects other pathways in the pathobiology of heart 
disease. Measurement of galectin-3 levels in acute 
phase of MI can provide additional useful informa-
tion in this group of patients, particularly indicating 
subjects at a higher risk for AF development. 
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